K. Hellmann

2.9k total citations
102 papers, 2.2k citations indexed

About

K. Hellmann is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, K. Hellmann has authored 102 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 18 papers in Molecular Biology and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in K. Hellmann's work include Cancer Treatment and Pharmacology (13 papers), Lung Cancer Treatments and Mutations (9 papers) and Colorectal Cancer Treatments and Studies (7 papers). K. Hellmann is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Lung Cancer Treatments and Mutations (9 papers) and Colorectal Cancer Treatments and Studies (7 papers). K. Hellmann collaborates with scholars based in United Kingdom, United States and Canada. K. Hellmann's co-authors include Rosemary I. Hawkins, E.O. Field, A. J. Salsbury, A. M. Creighton, J. S. Weiner, D. F. Tucker, Erik Herman, V J Ferrans, Brian B. Hasinoff and H. Blaschko and has published in prestigious journals such as Nature, The Lancet and Journal of Clinical Oncology.

In The Last Decade

K. Hellmann

99 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K. Hellmann United Kingdom	27	724	668	338	330	213	102	2.2k
John J. Rinehart United States	27	988 1.4×	1.0k 1.5×	461 1.4×	141 0.4×	234 1.1×	67	2.9k
Yutaka Tomoda Japan	36	629 0.9×	1.1k 1.6×	282 0.8×	203 0.6×	236 1.1×	253	4.2k
Guy Boileau Canada	35	1.1k 1.5×	1.7k 2.6×	142 0.4×	217 0.7×	275 1.3×	128	3.6k
Mary Ann Accavitti United States	19	392 0.5×	1.2k 1.8×	109 0.3×	113 0.3×	159 0.7×	31	3.3k
Lajos Gera United States	29	528 0.7×	1.3k 1.9×	533 1.6×	205 0.6×	142 0.7×	106	2.8k
Kenji Sugita Japan	23	538 0.7×	1.4k 2.1×	117 0.3×	170 0.5×	350 1.6×	83	2.9k
Teruhiko Inoue Japan	22	442 0.6×	776 1.2×	101 0.3×	178 0.5×	310 1.5×	56	1.8k
Terutoshi Kimura Japan	29	376 0.5×	2.3k 3.4×	155 0.5×	213 0.6×	227 1.1×	119	3.4k
Geneviève Durand France	27	249 0.3×	1.2k 1.8×	127 0.4×	311 0.9×	78 0.4×	78	2.3k
C J Edgell United States	11	282 0.4×	873 1.3×	131 0.4×	126 0.4×	246 1.2×	13	2.3k

Countries citing papers authored by K. Hellmann

Since Specialization

Citations

This map shows the geographic impact of K. Hellmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Hellmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Hellmann more than expected).

Fields of papers citing papers by K. Hellmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Hellmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Hellmann. The network helps show where K. Hellmann may publish in the future.

Co-authorship network of co-authors of K. Hellmann

This figure shows the co-authorship network connecting the top 25 collaborators of K. Hellmann. A scholar is included among the top collaborators of K. Hellmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Hellmann. K. Hellmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sargent, Jean, et al.. (2001). Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562. British Journal of Cancer. 84(7). 959–964. 26 indexed citations

Hasinoff, Brian B., K. Hellmann, Erik Herman, & V J Ferrans. (1998). Chemical, Biological and Clinical Aspects of Dexrazoxane and Other Bisdioxopiperazines. Current Medicinal Chemistry. 5(1). 1–28. 131 indexed citations

Hellmann, K.. (1996). Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): Progress in supportive care. Supportive Care in Cancer. 4(4). 305–307. 12 indexed citations

Hellmann, K., et al.. (1993). High dose dexamethasone and base of brain irradiation for hormone refractory metastatic carcinoma of the prostate. Clinical & Experimental Metastasis. 11(2). 227–229. 8 indexed citations

Hellmann, K.. (1992). Angiogenesis — Time to review progress. Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions. 61. 26–28. 3 indexed citations

Hellmann, K.. (1991). Radiotherapeutic enhancement by razoxane. Cancer Treatment Reviews. 18(4). 225–240. 19 indexed citations

Koning, J. de, et al.. (1991). Cardioxane—ICRF-187 towards anticancer drug specificity through selective toxicity reduction. Cancer Treatment Reviews. 18(1). 1–19. 47 indexed citations

Lichtner, Rosemarie B., Gillian Hutchinson, & K. Hellmann. (1989). The pyrimido-pyrimidine derivatives RA233 and RX-RA85 affect cell cycle distribution of two murine tumour cell lines. European Journal of Cancer and Clinical Oncology. 25(6). 945–951. 5 indexed citations

Hellmann, K.. (1986). Antimetastatic drugs: function and value.. PubMed. 212. 1–16. 2 indexed citations

10.

Hellmann, K., P. Hilgard, & Sue Eccles. (1980). Metastasis, clinical and experimental aspects : proceedings of the EORTC Metastasis Group International Conference on Clinical and Experimental Aspects of Metastasis, London, April 21-23, 1980. 1 indexed citations

11.

Hellmann, K., et al.. (1978). Combination of radiation and razoxane (ICRF 159) in vivo. International Journal of Radiation Oncology*Biology*Physics. 4(1-2). 109–113. 5 indexed citations

12.

Hellmann, K., et al.. (1974). Synergism of ICRF 159 and radiotherapy in treatment of experimental tumors. Cancer. 34(4). 1033–1039. 40 indexed citations

13.

Hallowes, R. C., et al.. (1974). Cumulative Cytostatic Effect of ICRF 159. Nature. 247(5441). 487–490. 26 indexed citations

14.

Rhomberg, W., K. Hellmann, & R. D. H. Ryall. (1974). Strahlentherapie und ICRF 159 (NSC 129943) in der Behandlung inoperabler Weichteilsarkome. DMW - Deutsche Medizinische Wochenschrift. 99(48). 2438–2442. 5 indexed citations

15.

Hellmann, K., et al.. (1972). Metastases and the Normalization of Tumour Blood Vessels by ICRF 159: A New Type of Drug Action. BMJ. 1(5800). 597–601. 113 indexed citations

16.

Hellmann, K., et al.. (1969). Preliminary Clinical Assessment of I.C.R.F. 159 in Acute Leukaemia and Lymphosarcoma. BMJ. 1(5647). 822–824. 43 indexed citations

17.

Hellmann, K., et al.. (1968). Antilymphocytic serum and tumour dissemination.. BMJ. 2(5604). 533–535. 19 indexed citations

18.

Hellmann, K., et al.. (1967). The antitumour activity of a series of benzothiophenes. Biochemical Pharmacology. 16(4). 681–687. 13 indexed citations

19.

Hellmann, K.. (1966). IMMUNOSUPPRESSION BY THALIDOMIDE: IMPLICATIONS FOR TERATOLOGY. The Lancet. 287(7447). 1136–1137. 17 indexed citations

20.

Hellmann, K., et al.. (1965). Prolongation of Skin Homograft Survival by Thalidomide. BMJ. 2(5463). 687–689. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact